Walking and Dietary Modification for Recurrent Early Miscarriages (W&D)
Primary Purpose
Recurrent Miscarriage
Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Walking & dietary modification
Sponsored by
About this trial
This is an interventional prevention trial for Recurrent Miscarriage focused on measuring prevention, carbohydrate, exercise, neonatal hypoglycemia
Eligibility Criteria
Inclusion Criteria:
- ≥ 2 consecutive pregnancy losses in the first trimester;
- losses should be documented by pathology or ultrasound-confirmed gestational sac.
Exclusion Criteria (any of the following):
- anatomic anomalies that may increase the risk of pregnancy losses, not amenable to surgical correction during pregnancy, such as uterine septum;
- antiphospholipid antibodies;
- prior second- or third-trimester losses;
- current multiple gestation;
- disabilities such as hemiplegia or paraplegia;
- renal or liver failure;
- conditions requiring a priori anticoagulation
Sites / Locations
- Hospital Federal dos Servidores do Estado, Ministry of Health
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Walking & dietary modification (W&D)
Controls
Arm Description
W&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W&D at enrolment and at each consultation.
No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.
Outcomes
Primary Outcome Measures
Take-home Baby Rate
Secondary Outcome Measures
Gestational Diabetes Mellitus
Preeclampsia
Mothers Who Used Heparin for Nephrotic Range Proteinuria or Placental Insufficiency
Excessive Weight Gain
Weight gain >13 kg for underweight, normal weight or overweight mothers and > 9 kg for obese mothers
First-trimester Losses
Second and Third-trimester Losses
Live-born Children
Babies Born at Term
Appropriate-for-gestational Age Babies
Neonates With Hypoglycemia
Hypoglycemia was defined as any blood glucose concentration ≤ 40 mg/dL.
Full Information
NCT ID
NCT03023137
First Posted
January 13, 2017
Last Updated
April 6, 2017
Sponsor
Hospital dos Servidores do Estado do Rio de Janeiro
1. Study Identification
Unique Protocol Identification Number
NCT03023137
Brief Title
Walking and Dietary Modification for Recurrent Early Miscarriages
Acronym
W&D
Official Title
Walking and Dietary Modification for Women With Consecutive Early Miscarriages: a Randomized Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
February 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital dos Servidores do Estado do Rio de Janeiro
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is part of a big one aiming to evaluate how lifestyle interventions during pregnancy affect obstetric results, neonatal metabolism and the intelligence of the offspring (study not yet completed). Data regarding obstetric and neonatal results were entered in NCT01409382, but we decided to split results in two for the sake of clarity.
A cohort of women with early pregnancy losses without antiphospholipid antibodies was selected for two reasons. One is that these women follow strictly the recommendadtions. The second is that no medication has been shown to increase the rate of take-home babies in women with early miscarriages who test negative for antiphospholipid antibodies. We decided to focus on the fibrinolytic system because trophoblast migration and placental vasculogenesis and angiogenesis depend on plasmin-dependent extracellular matrix remodeling. Plasminogen activator inhibitor (PAI)-1 inhibits the generation of plasmin. Since both glucose and insulin increase PAI-1 synthesis, hyperglycemia itself, or by stimulating insulin production, reduces plasmin generation, which may impair placentation.
Abnormalities in glucose metabolism may be also deleterious to embryos by causing epigenetic changes. Chromosomal abnormalities are considered an important cause of early pregnancy losses.
Several lines of evidence lend support to the hypothesis that carbohydrate metabolism abnormalities contribute to the pathogenesis of recurrent early pregnancy losses. One is that of the pregnancies of the women with polycystic ovary syndrome, around 30 and 50% end with first-trimester miscarriages. Hyperinsulinemia is a prevalent feature of the syndrome, and interventions proven effective in reducing insulin levels, such as metformin, have been shown to reduce the rate of early miscarriages. The other is that patients with body mass index of ≥25 kg/m2 have significantly higher odds of early miscarriage, regardless of the method of conception.
The investigator's hypothesis was that a balanced diet combined to regular exercise, by improving glucose homeostasis, would increase the take-home baby rate in women with consecutive early miscarriages. Moderate exercises are usually well tolerated not only by the mother, but also by the fetus, as indicated by tests of fetal well-being, including umbilical artery systolic to diastolic ratio.
Detailed Description
Women aged 18 to 40 years trying to conceive spontaneously were eligible if they had two or more consecutive pregnancy losses in the first trimester, documented by pathology or ultrasound-confirmed gestational sac.
All participants underwent ultrasound examination before inclusion in the study. Exclusion criteria were any of the following: anatomic anomalies that may increase the risk of pregnancy losses, not amenable to surgical correction during pregnancy, such as uterine septum; antiphospholipid antibodies; prior second- or third-trimester losses; current multiple gestation; disabilities such as hemiplegia or paraplegia; renal or liver failure; conditions requiring a priori anticoagulation.
Participants were enrolled by staff at the participating center. Randomization to the intervention protocol Walking and Diet (W&D) or to a control group was performed before pregnancy occurred by a statistician using a computer-generated random-number table. This was not a double blind study, but care was taken to ensure that appointments of the patients assigned to the intervention protocol did not coincide with those of controls.
The intervention was standardized by training of research staff. Women assigned to W&D were instructed to walk at a moderate pace (4 km/h) for at least 40 minutes, seven days a week. Besides, those who remained seated most of the day were advised to walk 25 to 30 minutes twice a day, avoiding hence more than 12 hours of physical inactivity. Walking could be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese. Strenuous exercises were discouraged.
Patients assigned to protocol W&D were also informed of the importance of a balanced diet and recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber). Sucralose could be used as a sweetener. As a strategy to promote satiety and reduce carbohydrate intake, W&D participants were also advised to eat at least two daily servings of protein-rich food. The intervention began when participants wished to conceive, continuing until delivery. Careful instructions about walking speed and diet were given to participants assigned to W&D at enrolment and at each consultation. During exercise, neither fetal nor maternal cardiac rate were assessed.
Non-adherence to the intervention protocol was suspected when non-obese participants assigned to W&D gained > 1 kg in 4 weeks until the 28th week of gestation, > 1.5 kg from the 28th to the 32nd week, and > 2 kg in 4 weeks thereafter, in the absence of edema. The threshold was lower for obese participants: > 700 g in 4 weeks until the 28th week of gestation, > 1 kg from the 28th to the 32nd week, and > 1.5 kg in 4 weeks thereafter21. Excessive weight gain aroused the suspicion of protocol violation because high carbohydrate consumption, especially when combined with physical inactivity stimulates the pancreas to overproduce insulin, a hormone that promotes fat storage. To enhance adherence to the protocol, W&D participants who gained excessive weight were recommended to increase the frequency, duration and intensity of the physical activity and to increase the protein intake. Participants of the W&D group who had a successful pregnancy volunteered to encourage mothers assigned to the intervention protocol, especially those who gained excessive weight.
At enrollment and during first-trimester consultations, W&D participants were explained that antiemetics such as ondansetron should be taken before nausea became severe, in order to help them tolerate balanced meals.
No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron were given to controls who complained of hyperemesis.
All participants were given folic acid tablets 5 mg daily until 14 weeks of gestation, as prevention of neural tube defects. In both groups, participants reporting abdominal pain, cramps, and vaginal bleeding during the first-trimester were medicated with vaginal progesterone. Subcutaneous heparin was given to all participants whose pregnancies were complicated with nephrotic range proteinuria or any evidence of placental insufficiency. Antihypertensive medications included methyldopa, amlodipine and hydralazine. No patient received aspirin or metformin in this study.
Appointments were scheduled according to the routine. Maternal weight and blood pressure were assessed at every appointment and all mothers were screened for gestational diabetes according to the American Diabetes Association recommendations.
Obstetric and neonatal outcomes were obtained from the hospital records. Neonates were classified as small, appropriate or large for gestational age according to Olsen et al. growth curves.
Written informed consent was obtained from each participant after a full explanation of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent Miscarriage
Keywords
prevention, carbohydrate, exercise, neonatal hypoglycemia
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Participants were not blinded, but visits of the two groups were scheduled so as to not coincide..
Allocation
Randomized
Enrollment
480 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Walking & dietary modification (W&D)
Arm Type
Active Comparator
Arm Description
W&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W&D at enrolment and at each consultation.
Arm Title
Controls
Arm Type
No Intervention
Arm Description
No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.
Intervention Type
Behavioral
Intervention Name(s)
Walking & dietary modification
Other Intervention Name(s)
W&D
Intervention Description
Daily walking at a moderate pace (4 km/h) > 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding >12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.
At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention
Primary Outcome Measure Information:
Title
Take-home Baby Rate
Time Frame
End of pregnancy
Secondary Outcome Measure Information:
Title
Gestational Diabetes Mellitus
Time Frame
Pregnancies reaching 24 weeks' gestation
Title
Preeclampsia
Time Frame
Pregnancies reaching 20 weeks' gestation
Title
Mothers Who Used Heparin for Nephrotic Range Proteinuria or Placental Insufficiency
Time Frame
End of pregnancy
Title
Excessive Weight Gain
Description
Weight gain >13 kg for underweight, normal weight or overweight mothers and > 9 kg for obese mothers
Time Frame
End of term pregnancies
Title
First-trimester Losses
Time Frame
14 weeks of gestation
Title
Second and Third-trimester Losses
Time Frame
28 weeks of gestation and end of gestation
Title
Live-born Children
Time Frame
End of pregnancy
Title
Babies Born at Term
Time Frame
End of pregnancy
Title
Appropriate-for-gestational Age Babies
Time Frame
End of pregnancy
Title
Neonates With Hypoglycemia
Description
Hypoglycemia was defined as any blood glucose concentration ≤ 40 mg/dL.
Time Frame
One, two and fours hours after birth
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
≥ 2 consecutive pregnancy losses in the first trimester;
losses should be documented by pathology or ultrasound-confirmed gestational sac.
Exclusion Criteria (any of the following):
anatomic anomalies that may increase the risk of pregnancy losses, not amenable to surgical correction during pregnancy, such as uterine septum;
antiphospholipid antibodies;
prior second- or third-trimester losses;
current multiple gestation;
disabilities such as hemiplegia or paraplegia;
renal or liver failure;
conditions requiring a priori anticoagulation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Silvia Hoirisch-Clapauch, MD, PhD
Organizational Affiliation
Hospital Federal dos Servidores do Estado
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Federal dos Servidores do Estado, Ministry of Health
City
Rio de Janeiro
State/Province
RJ
ZIP/Postal Code
20221-903
Country
Brazil
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Walking and Dietary Modification for Recurrent Early Miscarriages
We'll reach out to this number within 24 hrs